Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Isle Of Man, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Head and neck cancers are some of the most common types diagnosed in people over 50 years. Cancer begins around the mouth, sinus, nose, throat, and...
-
New York, USA, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain The...
-
Chicago, Jan. 30, 2023 (GLOBE NEWSWIRE) -- According to the new market research report "Pharmaceutical Drug Delivery Market Size, Growth by Route of Administration (Oral, Injectors, Implantable,...
-
NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
-
Dublin, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The "Joint Pain Injections Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
-
Dublin, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The "Global Glucagon-like Peptide 1 (GLP-1) Market: Analysis By Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products), By Route of...
-
Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their...
-
Dupixent® (dupilumab), premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement de l’œsophagite à éosinophiles Environ 60 % des patients de 12 ans et plus traités par...
-
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis Approximately 60% of patients aged 12 years and older treated...
-
Visiongain has published a new report entitled Monoclonal Antibody Discovery and Analysis 2022-2032. It includes profiles of Monoclonal Antibody Discovery and Analysis and Forecasts Market Segment by...